Skip to main content

Table 3 Crude and adjusted rate ratios for the association between the use of cardiac glycosides and lung cancer by varying the lag period to 6 months and 2 years and by additionally adjusting for sexual hormone intake in women

From: Cardiac glycosides use and the risk of lung cancer: a nested case–control study

Sensitivity analysis Cases Controls Crude RR Adjusted RR (95% CI)a
6-month lag period 1423 14,166   
  No use, n (%) 997 (70.1) 9843 (69.5) 1.00 1.00 (Reference)
  Ever use, n (%) 426 (29.9) 4323 (30.5) 0.97 1.08 (0.94 - 1.24)
2-year lag period 990 9850   
  No use, n (%) 703 (71.0) 6815 (69.2) 1.00 1.00 (Reference)
  Ever use, n (%) 287 (29.0) 3035 (30.8) 0.91 1.02 (0.86 - 1.20)
Additionally adjusting for HRT/OC use in women 419 4183   
  No use, n (%) 295 (70.4) 2828 (67.6) 1.00 1.00 (Reference)
  Ever use, n (%) 124 (29.6) 1355 (32.4) 0.88 0.97 (0.74 - 1.27)
  1. aAdjusted on smoking status BMI indication of CG use excessive alcohol use history of tobacco-related conditions history of lung diseases factors associated with sexual hormonal disorders drugs potentially associated with lung cancer (statins aspirin oral anticoagulants and antiplatelets non-steroidal anti-inflammatory drugs anti-hypertensives oral bisphosphonates anti-diabetic drugs) and amiodarone.
  2. RR Rate ratio, HRT Hormone replacement therapy, OC Oral contraceptive).